Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Case Report: Rheumatoid Arthritis-Associated Restrictive Pericarditis

Scott Rodriguez, MD, Kenton Powell, MD, & Daniel Albert, MD  |  Issue: November 2019  |  November 17, 2019

Following two infusions of 1,000 mg rituximab eight weeks apart, the patient’s symptoms resolved.

Following two infusions of 1,000 mg rituximab eight weeks apart, the patient’s symptoms resolved.

Supawit Srethbhakdi / shutterstock.com

Rheumatoid arthritis (RA) is a systemic autoimmune disease that affects approximately 1% of the adult population, and involvement of extra-articular tissue occurs in approximately 40% of patients over their lifetimes.1 RA-associated pericardial disease is an uncommon complication, and surgery is the only definitive therapy—according to current literature.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In this report, we present the case of a 57-year-old man with rheumatoid factor and anti-CCP-positive RA who developed restrictive pericarditis that resolved with initiation of anti-CD20 therapy—offering a potentially novel and surgery-sparing therapy to treat a rare, highly mortal complication of RA.

The Case

A 57-year-old man presented to a general internal medicine clinic with shortness of breath and a cough that he’d had for about a month.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Four weeks prior to presentation, the patient developed worsening shortness of breath with exertion. The symptoms were stable and did not progress over the initial three weeks, but over the week prior to his presentation, he began to experience increased global fatigue with worsening dyspnea. He had an intermittent, non-productive cough. He denied a history of fever, chills, weight change, lightheadedness, exertional chest discomfort, palpitations, orthopnea, paroxysmal nocturnal dyspnea, lower extremity edema, cough, wheeze, focal weakness or myalgia.

Medical history: The patient’s medical history was significant for RA—he was diagnosed at age 53—complicated by interstitial lung disease (ILD), for which he was taking 20 mg of methotrexate weekly and 50 mg of etanercept weekly. He also has Graves’ disease, complicated by ophthalmopathy, for which he was taking 10 mg of methimazole daily. He suffers from depression and anxiety, for which he was taking 40 mg of citalopram daily, 150 mg of buproprion twice daily and 0.5 mg of lorazepam as needed.

Table 1: Initial Lab Work

(click for larger image) Table 1: Initial Lab Work

Physical examination: The patient’s physical examination was notable for inspiratory crackles at the left base posteriorly with an elevated jugular venous pressure but no evidence of pulsus paradoxus.

Laboratory tests & imaging: Results of his laboratory evaluation were notable for interval elevation of his previously normal C-reactive protein and sedimentation rate, as well as his pro-brain natriuretic peptide level (see Table 1).

A chest X-ray demonstrated interval enlargement of the cardiomediastinal silhouette, with increased bilateral hilar, and vascular markings concerning for pulmonary edema with small bilateral pleural effusions.

An electrocardiogram showed a normal sinus rhythm at a rate of 80 beats per minute with normal intervals and diffuse low voltage. An echocardiogram revealed a moderate, circumferential pericardial effusion with subtle right ventricular diastolic collapse and less than 50% respiratory change in the inferior vena cava, consistent with elevated right atrial pressures.

Clinical Course

The patient was referred to a cardiologist after his initial presentation, and ultimately the patient deferred admission for pericardiocentesis, preferring outpatient therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine for presumed restrictive pericarditis.

At his one-month follow-up appointment, the patient reported the intervals between bouts of shortness of breath, associated with new-onset hypoxemia, were shorter. Cardiac magnetic resonance imaging (MRI) was obtained on an emergent basis. It demonstrated thickening of the visceral and parietal pericardium with a moderate effusion, concerning for worsening of his previously demonstrated restrictive pericarditis. The MRI was also notable for mild left ventricular hypokinesis. Consequently, the patient was admitted to the cardiology unit for a right and left heart catheterization. Intrathoracic intraventricular dissociation and a positive Kussmaul sign consistent with restrictive physiology were noted.

A surgeon was consulted to discuss a potential pericardiectomy, but the procedure was considered to be high risk for the patient given concurrent active inflammatory disease and his known history of interstitial lung disease with a new left-sided effusion of unclear etiology.

The patient subsequently had a thora­centesis performed. The fluid studies showed a lactate dehydrogenase (LDH) level of 1,886 IU/L, protein of 4.6 g/dL and glucose <2 mg/dL. The infectious workup was negative. The results were consistent overall with an inflammatory effusion likely secondary to his poorly controlled RA.

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsRheumatoid Arthritis Tagged with:anti-CD20 therapyPericarditisrituximab

Related Articles
    Case Report: Cardiac Tamponade in a Rheumatoid Arthritis Patient

    Case Report: Cardiac Tamponade in a Rheumatoid Arthritis Patient

    October 18, 2019

    Rheumatoid arthritis (RA) is a chronic systemic autoimmune inflammatory disease. Although RA develops its central pathology within the synovium of diarthrodial joints, many non-articular organs can be involved, particularly in patients with severe joint disease.1 Although most patients are asymptomatic, cardiac involvement is relatively common and includes rheumatic heart nodules, pericarditis (30–50%), pericardial effusion and…

    The Heart-SCC Puzzle

    May 1, 2009

    Identifying and treating cardiac involvement in systemic sclerosis can be a challenge

    Case Report: Drug-Induced Lupus

    September 14, 2021

    The incidence of drug-induced lupus continues to rise as clinicians expand their therapeutic armamentarium. An estimated 15,000–30,000 cases of drug-induced lupus occur every year in the U.S. alone.1 It is a well-known, but rare, complication of commonly used medications, such as anti-hypertensive, anti-arrhythmic and anti-epileptic drugs, as well as biologic and immune checkpoint therapies.2,3 The…

    Colchicine Effective for Acute Pericarditis

    October 25, 2013

    Patients with acute pericarditis who are treated with colchicine in combination with a traditional antiinflammatory therapy experience a significantly reduced rate of incessant or recurrent pericarditis.  (posted Oct. 31)

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences